Cost-Effectiveness Analysis of Boceprevir for the Treatment of Chronic Hepatitis C Virus Genotype 1 Infection in Portugal

Abstract

Adding boceprevir to PR was projected to reduce the number of liver complications and liver-related deaths, and to be cost effective in treating both previously untreated and treated patients.

Assessing the Effect of Potential Reductions in Non-Hepatic Mortality on the Estimated Cost-Effectiveness of Hepatitis C Treatment in Early Stages of Liver Disease

“…This first step is an attempt to make mortality rates more realistic for an HCV-infected population, which have demographics and behaviors associated with mortality rates that are higher than those of the general population. This type of non-hepatic mortality modeling has been done by Elbasha et al in a sensitivity analysis [13] and done by others in their base case analyses [12]. This first step, taken in isolation, does not assume that successful HCV treatment has any effect on these higher background mortality rates.…”

“…Many modeling studies make no adjustment of background mortality [10, 11]. Other studies essentially only implement step one [12, 13], and still other studies implement both step one and step two [14–16]. …”

“…Some studies assume HCV-infected individuals experience background mortality at the same age-adjusted rate as the general population [10, 11]. Some studies assume HCV-infected individuals have higher background mortality rates than the general population, but that successful HCV treatment does not affect this mortality rate [12, 13]. Still other studies assume HCV-infected individuals have higher background mortality rates and that successful HCV treatment reduces this mortality rate [14–16].…”

Pricing of forthcoming therapies for hepatitis C in Europe: beyond cost-effectiveness?

“…Since five FEEs did not concern the EU setting, we eventually selected six articles [13][14][15][16][17][18] (Table 1).…”

Boceprevir for Chronic Genotype 1 Hepatitis C Virus in the Current Health Care Setting in Greece: A Cost-effectiveness Analysis

“…6 The estimated mean direct cost per patient in those without cirrhosis was €642/y (€1 ¼ US $1.30). 7 Costs related to the management of severe liver disease appeared to increase significantly, ranging from €5934/y 5 in patients with decompensated cirrhosis to 4€35,000/y in the first year after liver transplantation. 5 HCV is a "clever" virus, taking advantage of the host to replicate at 10 13 new virions per day, resulting in diverse genetic types.…”